FDA Neuro Panel Will Review Cyberonics, Confluent Postmarket Data
This article was originally published in The Gray Sheet
Executive Summary
FDA's Neurological Devices Panel will consider post-approval study data for Cyberonics' implantable VNS Therapy for treatment-resistant depression and for Tyco/Confluent Surgical's DuraSeal cranial surgery sealant system Jan. 26, FDA announced Dec. 22
You may also be interested in...
FDA Panel Gives Thumbs Up To DuraSeal Xact Spine Surgery Sealant
Covidien's DuraSeal Xact dural repair sealant for spine surgery should be approved with conditions, FDA's Neurological Devices panel recommended in a unanimous 4-0 vote May 14
FDA Panel Gives Thumbs Up To DuraSeal Xact Spine Surgery Sealant
Covidien's DuraSeal Xact dural repair sealant for spine surgery should be approved with conditions, FDA's Neurological Devices panel recommended in a unanimous 4-0 vote May 14
FDA Aims To Up Transparency By Making Panel Materials Public Sooner
FDA will post advisory committee briefing materials on its Web site at least two business days in advance of meetings, doubling the current lead time in an effort to enhance transparency, according to a 1draft guidance released last week